Mucosal-surface immune function discoveries could boost vaccine research

June 14, 2007

In a finding that could have important implications for HIV vaccine research, new research at Weill Cornell Medical College illuminates the ways in which the body prevents its mucosal surfaces from being overwhelmed by bacteria.

Bacteria, most of them "friendly," appear in huge quantities along the intestinal wall, the mouth, nose and throat, and the anal and urogenital tracts. Now, groundbreaking research at Weill Cornell shows that the epithelial cells that line these mucosal surfaces help guide the immune system's efforts to keep bacteria in check.

"That's a wholly new finding, since most biologists think of epithelial cells as a barrier cell -- not as a highly active player in immune function," explains senior researcher Dr. Andrea Cerutti, associate professor in the Department of Pathology and Laboratory Medicine at Weill Cornell Medical College.

"Armed with this knowledge, perhaps we can harness the mechanisms we've discovered to ward off more dangerous pathogens that use mucosal surfaces as their point of entry into the body -- viruses such as HIV, or rotavirus, the diarrhea pathogen that kills millions of children in poor countries each year," he explains.

His team published their findings in the June issue of Immunity.

The new research focused on a type of protective immune system antigen called immunoglobulin A (IgA), which is produced by immune system B cells. In humans, IgA takes two forms -- IgA1 and IgA2.

IgA2, especially, is found in high concentrations along mucosal sites wherever friendly, "commensal" bacteria abound, such as in the intestine where these germs aid in digestion. "Of course, left unchecked, even these bacteria could overrun the gut and cause harm," Dr. Cerutti says. "But somehow the immune system keeps them in balance, giving us the bacteria's benefits with no dangers."

IgA2 is a key player in this balancing act, but since there are many types of IgA antigens, how do local B cells know to produce this variety"

The new cell-culture experiments performed at Weill Cornell solve that riddle. "The answer lies in a surprising place -- the billions of epithelial cells that line the gut, urogenital tract and respiratory mucosa," explains co-lead author Dr. Bing He, an investigator in the Department of Pathology and Laboratory Medicine. Up to now, biologists have typically thought of epithelial cells as merely a tight wall or barrier shielding the body from outside invaders.

"However, our work suggests that these cells also act in an immunological way in the presence of commensal bacteria," Dr. He says. "Using specific receptors on their surface, epithelial cells sense the presence of abundant bacteria and start producing a factor called APRIL. APRIL, a cytokine-signaling chemical, essentially tells nearby B-cells to start producing the IgA2 antigen."

IgA2 helps the immune system keep mucosal bacteria in check. So, as bacteria levels rise, so too do levels of IgA2, dampening the excessive growth of these otherwise helpful bugs.

And there is one more twist to the story.

"We have also discovered that epithelial cells cross-talk with another big immune system player called dendritic cells," says co-first author Dr. Weifeng Xu, another researcher in the Department of Pathology and Laboratory Medicine. Dendritic cells are the body's key immune "sensors" dedicated to spotting possible threats.

"Using another signaling route, epithelial cells in the mucosal lining tell dendritic cells to boost their own production of APRIL. That ratchets up IgA2 production even more," Dr. Xu says.

The bottom line: Epithelial cells in the mucosa appear to be a major new player in the immune defense of these vulnerable surfaces.

"That's really important, because we now want to know how crucial IgA is to the neutralization of HIV, rotavirus or other pathogens," adds Dr. Daniel Knowles, a study co-author and chairman of the Department of Pathology and Laboratory Medicine at Weill Cornell.

Dr. Cerutti agrees that these discoveries are probably just the beginning.

"A better understanding of how the body fights off mucosal pathogens helps us immensely when we try and develop vaccines that target these areas," he explains. "By taking advantages of these mechanisms, we should move that much closer to interventions that shield millions against potentially lethal infections."

Source: New York- Presbyterian Hospital

Explore further: Fish oil component preconditions vision cells to survive future injury or disease

Related Stories

Fish oil component preconditions vision cells to survive future injury or disease

November 30, 2017
A team of LSU Health New Orleans scientists discovered that a component of fish oil not only protects cells critical to vision from potentially lethal initial insults, but also from those that occur in the future. The study ...

When a common cold may trigger early supportive care

December 6, 2017
Human rhinovirus (HRV), the culprit behind most colds, is the leading cause of hospitalization for premature babies. However, in very preterm children, exactly how HRV causes severe respiratory disease—and which patients ...

Immune cells produce wound healing factor, could lead to new IBD treatment

September 20, 2017
Specific immune cells have the ability to produce a healing factor that can promote wound repair in the intestine, a finding that could lead to new, potential therapeutic treatments for inflammatory bowel disease (IBD), according ...

Researchers produce the first draft cell atlas of the small intestine

November 8, 2017
The lining or epithelium of the gut is one of the body's most diverse and dynamic tissues, an ecosystem of cells that acts as one of the body's main interfaces with the outside world. To better understand this complex tissues ...

APC protein affects colon cancer immunity by preventing pre-cancerous inflammation

October 25, 2017
Adenomatous polyposis coli (APC) is a gene whose mutations are associated with a rare, hereditary form of colorectal cancer known as familial adenomatous polyposis. Research led by scientists at the Institut Pasteur and Inserm ...

E-cigarettes may trigger unique and potentially damaging immune responses

October 20, 2017
E-cigarettes appear to trigger unique immune responses as well as the same ones that cigarettes trigger that can lead to lung disease, according to new research published online in the American Thoracic Society's American ...

Recommended for you

Study suggests a way to stop HIV in its tracks

December 1, 2017
When HIV-1 infects an immune cell, the virus travels to the nucleus so quickly there's not enough time to set off the cell's alarm system.

Discovery puts the brakes on HIV's ability to infect

November 30, 2017
Viewed with a microscope, the virus faintly resembles a pineapple—the universal symbol of welcome. But HIV, the virus that causes AIDS, is anything but that. It has claimed the lives of more than 35 million people so far.

Rising levels of HIV drug resistance

November 30, 2017
HIV drug resistance is approaching and exceeding 10% in people living with HIV who are about to initiate or reinitiate first-line antiretroviral therapy, according to the largest meta-analysis to date on HIV drug resistance, ...

Male circumcision and antiviral drugs appear to sharply reduce HIV infection rate

November 29, 2017
A steep drop in the local incidence of new HIV infections accompanied the rollout of a U.S.-funded anti-HIV program in a large East-African population, according to a study led by researchers at Johns Hopkins Bloomberg School ...

Combination HIV prevention reduces new infections by 42 percent in Ugandan district

November 29, 2017
A study published today in the New England Journal of Medicine provides real-world evidence that implementing a combination of proven HIV prevention measures across communities can substantially reduce new HIV infections ...

Research on HIV viral load urges updates to WHO therapy guidelines

November 24, 2017
A large cohort study in South Africa has revealed that that low-level viraemia (LLV) in HIV-positive patients who are receiving antiretroviral treatment (ART) is an important risk factor for treatment failure.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.